Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
May 6, 2024
Earnings Call Speaker Segments
Zack Kubow
executiveThanks a lot, operator, and hello to all of you this afternoon. I appreciate everyone being with us for Corvus Pharmaceuticals' conference call covering our First Quarter 2024 Business Update and Financial Results. Here to talk through the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lee, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Jim Rosenbaum, Senior Vice President of Research; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Our executive team is going to kick things off with a few prepared remarks, and after that we'll move into a question-and-answer session. I want to remind all of you that the comments management makes today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today, and they carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' annual report on Form 10-K and other filings the company makes with the SEC from time to time. Unless the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements. With that said, I'll hand the call over to Leiv Lei. Leiv?
Leiv Lea
executiveThanks, Zack. I'll start by giving you a brief look at our financial results for the first quarter of 2024, and after that I'll hand things over to Richard for an update on the business. R&D expenses came to $4.1 million in Q1 2024, versus $4.6 million during the comparable period in 2023. We posted a net loss of $5.7 million for the first quarter of 2024, which included $0.2 million of noncash income tied to Angel Pharmaceuticals, our partner in China. That's against a net loss of $7.9 million in the same period of 2023, when we recorded a $1.7 million noncash loss connected to Angel Pharmaceuticals. Total stock compensation expense reached $0.7 million in the first quarter of 2024, compared with $0.5 million a year earlier. At March 31, 2024, Corvus held cash, cash equivalents and marketable securities of $22.1 million, down from $27.1 million as of December 31, 2023. We closed a $30.6 million financing today, with participation from a leading group of biotech investors plus certain members of the Corvus leadership team. Taking into account the money raised in that financing, pro forma cash as of March 31, 2024, stood at roughly $52.7 million, which pushes our cash runway out to Q4 of 2025. I'll now pass the call to Richard, who will walk through our clinical progress and go into more detail on our strategy and plans.
Richard Miller
executiveThanks, Leiv, and hello everyone on this afternoon's call. We're glad you could take part as we walk through where the business stands. From the point in mid-March when we shared our Q4 update, we've continued making headway on 2 main value drivers that 2024 is centered on. The first one concerns the registrational Phase III study we have planned for soquelitinib in relapsed peripheral T-cell lymphoma patients — enrollment is still set to begin during the third quarter, and our conviction about this trial continues to strengthen, because 2 additional patients in our Phase I/Ib study have now recorded objective responses at their initial follow-up. Also, regarding the Phase I study of soquelitinib that uses a placebo control and involves individuals suffering from atopic dermatitis of a moderate to severe nature, we started signing up participants during April. That means we remain on schedule to share preliminary results from this trial prior to the conclusion of this year. In addition to those two soquelitinib objectives, we now have positive early findings to share from our Phase Ib/II study of ciforadenant — an adenosine A2A receptor antagonist — in patients facing frontline metastatic renal cell cancer, also known as RCC. Because the first group of patients showed a notably high rate of deep responses, the statistical threshold that was set in advance for growing the trial has now been satisfied, and the Kidney Cancer Research Consortium, or KCRC, is in the process of adding more participants. Along with the business development work we're doing to further unlock what ITK inhibition can offer across a wide range of oncology and autoimmune indications, we think Corvus is set up to keep creating value and moving our distinctive pipeline forward to help patients achieve better clinical outcomes. I'll now walk through our progress in more detail, beginning with soquelitinib for PTCL. We're not enrolling new patients in our Phase I trial anymore, but the data keeps changing as patients on therapy finish their scheduled follow-up assessments. As of our latest data cutoff on May 3, 2024, 2 more patients had achieved an objective response at their first follow-up visit. One patient had a complete response, which a PET CT scan verified. The other showed a partial response, with the tumor shrinking by more than 80% in volume. Both individuals presented with disease at multiple sites and had not responded to two earlier lines of treatment. Each of them remains on the drug. Adding these newly evaluable cases brings the objective response rate, or ORR, among Phase III eligible patients to 9 of 23, which equals 39% — comprising 5 complete responses plus 4 partial responses. While no head-to-head comparison exists, soquelitinib's 22% complete response rate comes in at roughly twice what has been observed with belinostat or pralatrexate, the conventional chemotherapies for PTCL against which we will test in our Phase III study. In the same way, this cohort's ORR, disease control rate, progression-free survival and overall survival stack up well against what has been observed with belinostat or pralatrexate. For the patients we treated, median PFS — the primary endpoint of the Phase III study — came in at 6.2 months. That is a strong showing next to figures published for the standard agents: 1.6 months with belinostat and 3.5 months with pralatrexate. The durability of our responses is remarkable, as several patients who joined the study earlier are still responding past 24 months. For relapsed PTCL, our plan is to begin enrollment in the registrational Phase III trial of soquelitinib in the third quarter of 2024. We're in advanced talks — not just working, but quite far along — with a number of top centers throughout the U.S. and Canada. About 40 sites should be participating in this study, and the large majority of those will be in the United States. Now, moving to a soquelitinib update in atopic dermatitis, the initial immune disease indication we're looking at: we started enrolling patients this past April in the study's first patient cohort. Because soquelitinib has several attractive features, physicians have expressed substantial interest in our study. First off, it's a first-in-class agent featuring a novel mechanism of action. Soquelitinib works by interfering early in the process to stop Th2 and Th17 cells, which means it winds up suppressing a large number of cytokines involved in disease. It also comes in an oral formulation, and in the cancer trials we ran, it showed an excellent safety profile. Beyond that, there's potential for it to help with many different autoimmune and inflammatory conditions, and this study could provide proof-of-concept for addressing additional immune diseases. Under the design, 64 patients will be enrolled—those with moderate to severe atopic dermatitis whose condition has worsened despite receiving at least one earlier treatment. The trial is randomized and placebo-controlled, with blinding applied to the patients as well as the physicians treating them. The study will include four groups enrolled one after another, each consisting of 16 individuals. Within each group, participants will be assigned in a 3:1 ratio to receive either soquelitinib—given in varying dose schedules—or a placebo, with treatment lasting 28 days. The main goal being evaluated is how safe and well-tolerated the drug is, whereas effectiveness will be judged using the Investigator Global Assessment along with the Eczema Area and Severity Index score, known as EASI, a measurement that has been clinically validated for tracking improvement. One important point: even though this is a double-blind trial, the company sponsoring it remains unblinded, and our plan is to keep examining the data on an ongoing basis whenever a cohort completes its enrollment. Beyond that, we will track concentrations of several serum cytokines both before treatment begins and during it. Findings from those tests might provide valuable biomarkers. Taking into account where enrollment is heading, the activations we're expecting at sites, and how long follow-up takes, we anticipate having data from the first cohorts in hand prior to the close of 2024, and the study should wrap up in early 2025. In addition to what we're doing in PTCL and atopic dermatitis, we're still putting together a soquelitinib trial in solid tumors, testing it both on its own and in combination with nivolumab, in relapsed RCC. We're also continuing to hold active conversations around corporate partnering. When it comes to business development, our approach is to identify partners who bring know-how in developing and commercializing immune disease therapies, while also going after regional oncology partnerships that fit well with what we do and know in cancer. I'm glad to share where things stand with ciforadenant, which is our antagonist targeting the adenosine A2A receptor. In developing ways to go after the adenosine A2A receptor for cancer treatment, we've been among the front-runners. Research put out over recent years, both preclinical and clinical, has shown that ciforadenant fights tumors on its own and also when paired with checkpoint inhibitors. Notably, in preclinical work we published in 2018, combining an anti-CTLA-4 antibody with ciforadenant yielded dramatic antitumor effectiveness across multiple animal models. Additional investigation has uncovered the likely reason behind this synergy: it works by modulating the tumor microenvironment, and more precisely, by blocking myeloid-derived suppressor cells. Put another way, our view is that for an A2A antagonist, anti-CTLA-4 antibodies make a far superior combination partner compared with anti-PD-1s. Those results paved the way for our work with the Kidney Cancer Research Consortium. This collection of institutions gathers the top physicians and researchers focused on kidney cancer, and their mission is finding better treatments for patients who have renal cancer. Our Phase Ib/II clinical trial, under the leadership of Dr. Katy Beckermann of Vanderbilt University Medical Center, is assessing ciforadenant as a possible first-line therapy for metastatic renal cell cancer, given together with ipilimumab and nivolumab. Enrollment is now available at MD Anderson, Vanderbilt, Duke and the University of Pennsylvania.
Richard Miller
executiveRight now, the clinical trial sits in its Phase II portion, and as a whole it's built to enroll as many as 60 patients. At present, more than 27 patients have been enrolled. The study uses a rigorous efficacy measure: deep response rate. That means the CR rate plus the PR rate, counting only those PRs that reached a tumor volume reduction above 50%. Keep in mind, the standard threshold for PRs is a 30% tumor reduction. According to data from the KCRC, deep response rate tracks with long-term progression-free survival and overall survival, and across their earlier studies it stands at 32% with ipilimumab and nivolumab. In an interim analysis, our protocol-defined prespecified statistical threshold for efficacy requires showing at least a 50% increase over that 32% deep response rate observed in prior ipi/nivo combination trials in renal cell cancer run by the Kidney Cancer Research Consortium. Put another way, we must surpass a deep response rate of 48%. As of May 2, 2024, the interim analysis that was carried out shows we have met the statistical threshold for efficacy, so the trial keeps enrolling patients. These results have us excited, because of the positive clinical implications for patients; what's more, they align with our laboratory and preclinical findings and, in our view, could point to a novel immunotherapy approach. To sum up the outlook for the rest of 2024: with our recent financing, our current cash provides runway into late 2025, which lets us reach several near-term milestones, among them: kicking off our registrational Phase III clinical trial of soquelitinib in PTCL during the third quarter; producing interim results from our soquelitinib Phase I atopic dermatitis trial before year-end, with final data to follow in early 2025; reporting further data from the ciforadenant Phase Ib/II clinical trial later this year; and launching a Phase II clinical trial with soquelitinib in solid tumors in the fourth quarter, with initial data expected in the second half of 2025. We're eager to share updates on our programs in the quarters ahead. I'll now hand the call over to the operator for a questions-and-answer period. Operator?
Aydin Huseynov
analystNice to see the advancement, and even more so the 2 extra responses in PR and CR. Coming out of Phase Ib, those are pretty surprising. Turning to soquelitinib in PTCL, you reported 23 patients, a DCR of 61%, 5 CRs, and 4 PRs; could you refresh our memory on what the benchmark for KCRs looks like in other PTCL trials, such as belinostat, pralatrexate, or other agents?
Richard Miller
executiveThanks, Aydin, for raising that; the trials that led to approval for belinostat as well as pralatrexate were single-arm in design. Roughly 15 years back, those drugs got accelerated approval. For each of them, CR rates came in at around 10%, while overall response rates landed near 25% to 30%; their PFS, meaning progression-free survival, ran approximately 1.5 to 3.5 months.
Aydin Huseynov
analystAll right, that's useful. And given these new responses, how much of a bump do you expect that to give your preliminary PFS and OS? From what I understand, you previously reported 6.2 months for PFS and 20 months for OS. Will there be a meaningful increase?
Richard Miller
executiveSo at present the ORR, meaning overall response rate, sits at 39%, just as a reminder. And incidentally, with lymphoma we apply the Lugano criteria, under which a PR requires 50%. I should also note that the PR I referred to shows roughly an 87% shrinkage of tumor. One tumor disappeared completely. My guess is he may soon be headed toward a CR. As for PFS, we anticipate it will get better as those final few patients progress past the median.
Aydin Huseynov
analystOkay, got it. And as for the Phase III trial data, when do you expect we might get an initial look at the readout? I realize this is a randomized study and a blinded one. But when do you anticipate we'll get that first view?
Richard Miller
executiveSo, it's a randomized study. It isn't blinded. I mean, we know which patients receive chemotherapy and which receive our drug; that's difficult to conceal in an oncology study because these agents — the chemo drugs — come with side effects. As I said, the median PFS for pralatrexate and belinostat is short, just a few months. So the trial isn't very long; it's 150 patients; we believe we could likely complete enrollment in roughly 18 months, and after that you'd need some follow-up to reach the final data. There is an interim — there's a juncture where we perform an interim analysis, which happens when half the events have occurred. The events are the PFS events. But that takes place so late in the trial that we'd likely hold off until the study ends to make a final determination; that said, we do have an independent data monitoring committee; and I suppose if the findings were sufficiently convincing or compelling, there might be an ethical justification to stop the study.
Aydin Huseynov
analystAlright, that's clear. And if I could squeeze in one final question...
Richard Miller
executiveLet me put it this way — my sense is that by the time 24 months have passed, you'll have results from this trial.
Aydin Huseynov
analystAll right. So around 26, 26. Okay; I'm attempting to grasp that these drugs appear to be effective, yet essentially there's 40% who fail to respond, correct, 39% according to DCR. Therefore, could there be a method to identify additional possible biomarkers for selecting or screening patients more inclined to respond? Yes.
Richard Miller
executiveSo, that's something we're actively pursuing; we constantly search for mutations in baseline immune status, and so forth. Yet you may recall that a few months back, we put into place — and I discussed this during conference calls — the baseline immune status, the absolute lymphocyte count, and then the number of prior therapies used. I'm glad to say that after we began applying those eligibility criteria, what we've observed is, I'd argue, not just a greater number of responses, but also, I'd say, the response has occurred more quickly in terms of its kinetics; thus, I believe those steps we took a few months ago, or perhaps a year ago by now, truly have had an impact. And those steps came from our improved grasp of how the mechanism of action works. So my expectation is that in a Phase III trial — we already understand this. In a Phase III trial, we'll enroll better patients. Their immune status will be better from the outset. Phase I trials tend to enroll sicker patients, simply because they've run out of the other — any other available therapies; therefore, I would anticipate our results might improve, and we keep examining various markers. However, up to now, aside from baseline immune status, I'm not sure — I don't know whether we possess a particular molecular marker.
Jeff Jones
analystCongratulations on the announcement, everyone. That's wonderful. And congratulations on the financing too. One thing I wanted to ask about soquelitinib: several of the responders in the Phase I were cutaneous T-cell lymphoma patients. Could you remind me whether cutaneous T-cell lymphoma patients are going to be part of the Phase III, and what effect that could have on the PFS?
Richard Miller
executiveAmong our 23, there are a couple of patients who had cutaneous T-cell lymphoma. In both cases, the cutaneous T-cell lymphoma had transformed. When large cell transformation occurs, the outlook is very poor; my point is that this isn't what you'd call typical CTCL. We won't be enrolling CTCL patients in the Phase III trial, since it truly is a separate disease. It gets treated with other drugs, and early on it can behave as a chronic condition. Someone with only skin involvement may have the disease for many years. Those aren't the patients this trial is discussing. But Jeff, I believe you've brought up something important that I neglected to say. We're seeing responses in cutaneous lymphomas, anaplastic lymphoma, peripheral T-cell lymphomas, and something called angioimmunoblastic, now referred to as T-follicular helper cell lymphoma. Under the microscope, these are very distinct histologies. Their patterns of spread through the body differ, and their mutations—genetic mutations—differ as well. Seeing activity across such a diverse group of lymphomas, of T-cell lymphomas, is again really consistent with our mechanism, which works by inducing a host antitumor response. It's also one of the motivating factors behind our belief that we can extend this into solid tumors. That's why we began preclinical work with solid tumors. That data has been presented and confirmed by others, and it's why we're also excited about exploring this drug in solid cancers. Did that answer your question?
Jeff Jones
analystYep, you certainly did. That was genuinely useful. Thank you for that. I have frequently been curious — somewhat curious — regarding those skin-related responses, which clearly tend to be favorable responses.
Richard Miller
executiveJeff, wait a moment. The responses that we observe among these skin-involved patients, describing them that way isn't accurate; they suffer from skin disease. They possess circulating tumor cells. They have lymphadenopathy. At times they have visceral disease. The responses that we have witnessed among the patients who respond aren't merely skin-related. They occur across the entire body. All right.
Jeff Jones
analystUnderstood. My apologies — that wasn't the best way to phrase it. Regarding the atopic dermatitis trial, you said, if I recall correctly, that participants had undergone 2 earlier lines of treatment. Will you be — do you plan to enroll people who have already tried dupilimab without success? Or does that — is that level of detail not something you're specifying?
Richard Miller
executiveThat level of detail isn't something we're specifying; and they must have not responded to at least 1 earlier treatment, 1 earlier therapy that's either systemic or topical. A portion of the patients — we expect that a portion of those entering our study will have not responded to dupi, though that isn't mandatory. They will have not responded to other treatments as well. I believe there's a recent patient of ours who did not respond to a JAK inhibitor, for instance. So essentially, we have to frame this — the purpose of this trial was genuinely to demonstrate, naturally, that the drug is well-tolerated within a patient population such as this. And we're seeking signs of activity. Clearly, afterward, we'll be attempting to determine whether it's — how it compares with some of these other agents. But at this point, we're verifying mechanisms, safety; and indeed, we are assessing efficacy versus the placebo.
Jeff Jones
analystUnderstood. Yes, I appreciate you making that clear. Then my final question concerns cifo. I recall you mentioned that 27 patients had been enrolled, yet you did not state how many of them were part of that interim efficacy analysis.
Richard Miller
executiveMy understanding is that 18 patients are in it. You're correct, since a number of them have not yet returned for their initial visit. Incidentally, this protocol was put together by the KCRC. And they have — the patients are grouped into blocks of, I can't recall exactly how many per block, 8 or 9 patients per block. And to keep going, you must meet a criteria efficacy threshold. The results we have so far are actually quite good. In fact, we're putting together a meeting at ASCO to consider talking about topics such as adding a control arm, or what our next step should be. Clearly, at some stage, having a control arm in there is something you want. Incidentally, that 32% deep response rate for ipi/nivo — I realize people always criticize historical controls, and rightly so, but that figure comes from a 900-patient CheckMate II — well, the CheckMate trial of ipi/nivo versus Sutent involved more than 900 patients, and then there was a nivo/cabo versus Sutent trial. That one had 700 patients; so a pretty solid data foundation underlies this.
Jeff Jones
analystUnderstood. I just need one point of clarification. During your prepared comments, I believe you said 27 were enrolled, and that once you crossed the threshold of deep responses, the trial would be expanded. Did you simply mean expanding further, up to the 60 that were planned? Or could there be an expansion past those 60 patients?
Richard Miller
executiveNo. Nothing beyond the 60. What I was referring to — when I brought up expansion, my thought was that at some stage it would be good to introduce a control arm, perhaps ipi/nivo by itself, or ipi/nivo plus placebo. But that likely — it brings up the larger issue of whether you'd rather run a randomized Phase II, or whether you'd prefer to move straight into a Phase III.
Graig Suvannavejh
analystThere are two things I want to ask about. First, perhaps I'll begin with your other asset. I recall you said you managed to clear, say, the efficacy bar needed to keep going. I'm not sure whether — maybe I overlooked it — you gave a figure for how far past that bar you actually went, based on, as I understand it, the 18 evaluable patients you had; so could you maybe provide additional detail there? Then second, regarding the cash you hold right now. Congratulations on the financing you just completed. But could you make clear if that money is enough to carry you through the Phase III trial of soquelitinib in PTCL?
Richard Miller
executiveAll right. Graig, I'll address the first point initially. The statistical cutoff stood at a 50% gain. So per the statisticians, a 50% gain on top of the 32%, which of course equals 48% — should you hit that, the difference comes with a P value of 0.1 across just 18 patients. That's a fairly demanding threshold. A 50% gain represents a substantial threshold. Well, we went beyond it. I'm unable to provide the precise figure since the KCRC would prefer not to reveal it at this stage, and I get the reasoning, given that in a small trial these figures swing considerably; even so, we are above a 48% deep response rate, all right? And if — once more, I want to stress, a 50% improvement in deep response rate is — that's a demanding threshold; the rationale for wanting it was that we had no desire to squander time on something lacking a meaningful likelihood of succeeding. So we set it — they didn't either; thus we intentionally made these thresholds quite rigorous. As for your second question, I'll have Leiv respond.
Leiv Lea
executiveGraig, regarding our financing, we also sold warrants. These warrants, to start with, come with an exercise price of $3.50, but perhaps more significantly, they expire on June 30, 2025, which is a little more than a year away. So if every one of those warrants were exercised, we'd bring in roughly $60 million. So the $30 million together with the $60 million, if those warrants do get exercised, would carry us through the Phase III trial.
Roger Song
analystThis is Riyan Chalan, filling in for Roger Song. We've got a few questions. The first one concerns soquelitinib and the revised inclusion criteria. Regarding the absolute lymphocyte count, around 900 — if my memory serves, there's substantial overlap in the 900-plus ALC range across the patient population. So could you explain what this group generally looks like?
Richard Miller
executiveOn the 900 absolute lymphocyte count, that threshold came from the trial's early stage, when we were enrolling anyone who'd failed any number of previous therapies. We noticed that patients above 900 fared better — considerably better. Then we realized those were patients with no more than 3 prior therapies, meaning less than or equal to 3 prior therapies. That's why we're applying this criterion — such patients are less immunocompromised. It's what has been applied to the patients described in today's press release. The prior therapy count is greater than or equal to 1 and less than or equal to 3. Now, I don't remember — apologies.
Analyst
analystIs there a general sense of how many individuals actually fit these requirements?
Richard Miller
executiveShould we look at our study, the proportion of subjects who qualify would be extremely large. Once more, during a Phase III study, physicians are already telling us they'll send us people immediately following an unsuccessful first-line treatment, possibly after a second-line treatment as well. My expectation is that almost 100% of patients would be suitable.
Analyst
analystUnderstood. Our next question concerns the AD trial. You said we might see an early data readout by the end of the year, so generally speaking, how much information should we anticipate from that?
Richard Miller
executiveI believe you should anticipate information from the initial two cohorts, and if you remember, our initial dose is 100 milligrams BID, which is a fairly strong dose. That dose is one we know engages the target, roughly 50% or so, more or less. While it isn't the optimal dose, it is still a fairly strong dose. The second cohort receives 200 milligrams, and after that we administered 200 BID. Therefore, I believe there's a strong chance we may observe some indications of efficacy in the initial cohort. In the second cohort, I would anticipate that we would observe it. Naturally, I believe it would be superior in later cohorts compared with the initial cohort. However, we are also examining those biomarkers, the serum cytokines that we know we influence and the way they will shift. Thus, I am hopeful that at some point before summer ends, we will begin to develop a sense of the drug's clinical activity as well as its impact on circulating cytokines.
Analyst
analystUnderstood. Regarding the dosing schedules, in a broad sense, how ought we to conceptualize the regimens for soquelitinib in AD, given that the indication differs from what is used in T-cell lymphoma?
Richard Miller
executiveAll right, what we know is — and this has been examined not just in lymphoma subjects, in T-cell lymphoma subjects, but also in other — in healthy individuals in vitro; we understand the amount required to saturate the T-cell — ITK within the T cells. Thus, as you may remember, it is a covalent medication comparable to how ibrutinib operates, except that it aims at another target. Consequently, after the medication attaches to the target, it will not detach. Therefore, we understand the amount required. We possess a very reliable pharmacodynamic indicator that tells us we are blocking the T-cells or at minimum occupying the T-cells. At present, we cannot be certain that the identical pharmacodynamics will be applicable in ADs as in lymphoma. That is, the occupancy will remain the same, yet the amount required to influence your immune response, that is something we do not know. That is the reason we are examining various doses within the study. The rationale for examining various doses is to determine the amount required to influence the immunology in these subjects and, naturally, to seek the lowest feasible level, since one would expect that a smaller dose would be safer. That is the reason this is a Phase I study. However, this is fundamental chemistry. Soquelitinib interacts with the ATP binding pocket of ITK, and that is the reality; that is what takes place; and after that is occupied, that enzyme will not function unless and until a new one is produced. So — and naturally, as you are aware, the rationale is that atopic dermatitis subjects possess a strong Th2-helper T-cell element in their condition. And we believe that if the medication reaches that location and attaches covalently to ITK, we are aware that we block Th2 cells, we are aware that we block Th2 cytokines, and we believe that will produce an effect on the condition. However, the aim of the trial is to demonstrate that.
Analyst
analystSure, let me try to fit in one more question. About the ITK inhibitors — I understand there are a few additional ones headed toward the clinic from your pipeline. So what would you point to as the main distinctions between soquelitinib and that other candidate?
Richard Miller
executiveWell, to start with, we've been assessing more than a dozen additional ITK inhibitors. A number of them have entirely distinct chemical structures; certain ones are covalent, while others are non-covalent. What's biologically intriguing, though, is that a few appear to influence T-cell — certain T-cell subsets to a greater degree than others. That strikes us as very interesting and quite novel, and it gives us, in my view, some rather robust intellectual property.
Rosemary Li
analystThis is Rosemary speaking in place of Li. We have just 2 quick questions. Regarding atopic dermatitis, is there any benchmark you use for improvement in Eczema Area and the Severity Index?
Richard Miller
executiveNo, there isn't a benchmark that we have.
Rosemary Li
analystAll right. All right. Then moving on to the second question: regarding your next-generation ITK inhibitors, are there any plans to produce human data for BD discussions, or will it be only the clinical?
Richard Miller
executiveMy apologies, I'm not able to grasp the question. Could you say it again?
Rosemary Li
analystApologies. Regarding your next-gen ITK inhibitors, do you intend to produce any human data prior to pursuing BD discussions?
Richard Miller
executiveWell, we're pursuing both at the same time; at this point we're picking out a few of these backup or second-generation ITK inhibitors. Those compounds are in their IND-enabling studies. We're scaling them up; we're advancing along parallel tracks. Alright. Operator, I believe that covers all our questions at this point. I'd like to thank — hello? Were there any other quarter questions I overlooked?
Richard Miller
executiveThanks, operator. I appreciate all of you joining us on this call today. We're eager to share more with you on upcoming calls, and we're grateful for your interest. Stay well.
Operator
operatorEveryone, that wraps up the call for today. We appreciate you joining us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.